AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab

Click here to view online. Add this email to your safelist.

11 September 2017

AstraZeneca today announced results from a subgroup analysis of the SIROCCO and CALIMA Phase III trials. The results confirm benralizumab’s compelling efficacy and identify key factors that predict which patients with severe, uncontrolled asthma would respond best to treatment with this potential new medicine.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.